| Literature DB >> 31632105 |
Maria Stańkowska1, Katarzyna Garbacz1, Lidia Piechowicz2, Marek Bronk3.
Abstract
BACKGROUND: In a recent decade, the occurrence of S. aureus isolates with low-level oxacillin resistance, have been reported increasingly. The aim of this study was to estimate the prevalence of S. aureus with low-level of oxacillin resistance and to determine their molecular characteristics, including spa types, SCCmec types and presence of toxin genes.Entities:
Keywords: MRSA; OS-MRSA; Staphylococcus aureus; borderline oxacillin-resistant S. aureus; low-level oxacillin resistance
Year: 2019 PMID: 31632105 PMCID: PMC6791403 DOI: 10.2147/IDR.S219557
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Characteristics Of Borderline Oxacillin-Resistant S. aureus
| Patient No. | Year | Origin | MIC Of Oxacillin (µg/mL) | Resistance To (DD, mm) | Phenotype Of Resistance | Coagulase Production | |||
|---|---|---|---|---|---|---|---|---|---|
| AD | E-Test | OX | FOX | ||||||
| 1 | t037 | 1998 | Wound | 4 | 2 | 12 R | 25 S | OX, E, CC, DX, GE, CIP, C | − |
| 2 | t037 | 2000 | Foot ulcer | 2 | 1 | 12 R | 26 S | OX, E, CC, DX, GE | − |
| 3 | t037 | 2000 | Wound | 2 | 1 | 11 R | 23 S | OX, E, DX, GE | − |
| 4 | t437 | 2013 | Furuncle | 4 | 2 | 14 S | 19 R | FOX, E, CC, TE, C | + |
| 5 | t437 | 2013 | Wound | 4 | 2 | 15 S | 19 R | FOX, E, CC, TE, C | + |
| 6 | t437 | 2013 | Wound | 4 | 2 | 14 S | 19 R | FOX, E, CC, TE, C | + |
| 7 | t437 | 2016 | Foot ulcer | 2 | 1 | 15 S | 18 R | FOX, E, CC, TE, C | + |
| 8 | t437 | 2017 | Wound | 4 | 2 | 13 S | 17 R | FOX | + |
| 9 | t437 | 2018 | Foot ulcer | 4 | 1.5 | 17 S | 19 R | FOX, E, CC, C | + |
| 10 | t216 | 2013 | Nose | 4 | 1.5 | 14 S | 16 R | FOX, E, CIP | + |
| 11 | t267 | 2016 | Blood | 4 | 4 | 15 S | 19 R | FOX, E | + |
| 12 | t015 | 2018 | Catheter | 4 | 2 | 18 S | 18 R | FOX, E, CIP | + |
Abbreviations: AD, agar dilution; DD, disk diffusion; OX, oxacillin; FOX, cefoxitin; E, erythromycin; CC, clindamycin; DX, doxycycline; TE, tetracycline; GE, gentamycin; CIP, ciprofloxacin; C, chloramphenicol; R, resistant; S, sensitive.
The Presence Of Virulence And Resistance Genes To β–Lactams Antibiotics In Different spa And SCCmec Types Of Borderline Oxacillin-Resistant S. aureus
| Patient No. | Repeat Succession | SCC | Genetic Profile | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | t037 | 15-12-16-02-25-17-24 | III | + | − | + | − | + | − | − | − | − | − | − |
| 2 | t037 | 15-12-16-02-25-17-24 | – | − | − | + | − | + | − | − | − | + | − | − |
| 3 | t037 | 15-12-16-02-25-17-24 | III | + | − | + | − | + | − | − | − | − | − | − |
| 4 | t437 | 04-20-17-20-17-25-34 | IV | + | − | + | + | − | − | − | − | − | − | − |
| 5 | t437 | 04-20-17-20-17-25-34 | IV | + | − | + | + | − | + | − | − | − | − | − |
| 6 | t437 | 04-20-17-20-17-25-34 | IV | + | − | + | + | − | + | − | − | − | − | − |
| 7 | t437 | 04-20-17-20-17-25-34 | IV | + | − | + | − | − | − | − | − | − | − | − |
| 8 | t437 | 04-20-17-20-17-25-34 | IV | + | − | + | + | − | + | − | − | − | − | − |
| 9 | t437 | 04-20-17-20-17-25-34 | IV | + | − | + | + | − | + | − | − | − | − | − |
| 10 | t216 | 04-20-17-20-17-31-16-34 | IV | + | − | + | − | − | + | − | − | − | − | − |
| 11 | t267 | 07-23-12-21-17-34-34-34-33-34 | IV | + | − | + | − | − | − | − | − | − | − | − |
| 12 | t015 | 08-16-02-16-34-13-17-34-16-34 | IV | + | − | + | − | − | − | − | − | − | − | − |
Figure 1Agarose gel image of lukS-PV/lukF-PV PCR amplicon (433 bp). Lane M – molecular size marker (pUC19 DNA/MspI enzyme, Fermentas, Lithuania); lanes 1-5 – representative PVL-positive S. aureus strains of spa type t437, lane 6 – negative control; lane 7 – positive control.
Characteristics Of Borderline Oxacillin-Resistant S. aureus spa Types t037 And t437
| Parameter | p-Value | ||
|---|---|---|---|
| Year of isolation | 1998–2000 | 2013–2018 | |
| Prevalence | 3/12 | 6/12 | 0.400 |
| Skin infection | 2/3 | 4/6 | 1.000 |
| Foot ulcer | 1/3 | 2/6 | 1.000 |
| SCC | 3/3 | 0/6 | |
| SCC | 0/3 | 6/6 | |
| 3/3 | 0/6 | ||
| 0/3 | 4/6 | 0.167 | |
| 0/3 | 5/6 | ||
| 1/3 | 0/6 | 0.333 | |
| Clindamycin/erythromycin resistance | 2/3 | 5/6 | 1.000 |
| Gentamicin/doxycycline resistance | 3/3 | 0/6 | |
| Production of coagulase | 0/3 | 6/6 |
Note: Bold values indicate statistical significance.